Jazz Pharmaceuticals (JAZZ)

• Market cap: $7.1B
• 1 day: 0.47%
• 5 days: 12.06%
• 1 month: -5.79%
• 3 months: -6.47%
• 6 months: 3.34%
• Year to date: -5.49%
• 1 year: 5.61%
• 5 years: 6.09%
• 10 years: -34.55%
• Sector: Healthcare
• Industry: Biotechnology

About: Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Employees: 2,800

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

131% more call options, than puts

Call options by funds: $17M | Put options by funds: $7.36M

65% more first-time investments, than exits

New positions opened: 91 | Existing positions closed: 55

13% more capital invested

Capital invested by funds: $6.42B [Q3] → $7.26B (+$843M) [Q4]

11% more funds holding in top 10

Funds holding in top 10: 9 [Q3] → 10 (+1) [Q4]

7% more funds holding

Funds holding: 470 [Q3] → 501 (+31) [Q4]

4.23% more ownership

Funds ownership: 93.38% [Q3] → 97.61% (+4.23%) [Q4]

1% more repeat investments, than reductions

Existing positions increased: 169 | Existing positions reduced: 168

Research analyst outlook

11 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $150 28% upside
• Avg. target: $191 63% upside
• High target: $230 97% upside

11 analyst ratings

• positive: 10 91%
• neutral: 1 9%
• negative: 0 0%

Needham Ami Fadia 22% 1-year accuracy 35 / 160 met price target	80% upside $210	Buy Reiterated	10 Apr 2025
HC Wainwright & Co. Oren Livnat 57% 1-year accuracy 28 / 49 met price target	86% upside $217	Buy Maintained	10 Mar 2025
Morgan Stanley Jeffrey Hung 15% 1-year accuracy 4 / 26 met price target	56% upside $183	Overweight Assumed	7 Mar 2025
UBS Ashwani Verma 25% 1-year accuracy 5 / 20 met price target	53% upside $179	Buy Upgraded	7 Mar 2025
Truist Securities Gregory Fraser 0% 1-year accuracy 0 / 2 met price target	97% upside $230	Buy Maintained	6 Mar 2025